Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343889 | 0.86 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3AOC3HTR7 | |
| SCHEMBL19545861 | 0.82 | ALOX5 (0.49) | ALOX5PTGS2TAAR1 | |
| SCHEMBL8564056 | 0.80 | CA1 (0.48) | ALOX5PTGS2HTR2ATAAR1 | |
| SCHEMBL9176631 | 0.79 | ALOX5 (0.46) | ALOX5PTGS2AOC3CHRM2TAAR1 | |
| Hydrochloric Acid SCHEMBL9176192 | 0.79 | PPARG (0.47) | SLC6A4SLC6A2SLC6A3PTGS2 | |
| SCHEMBL9174609 | 0.79 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3AOC3HTR7 | |
| SCHEMBL735118 | 0.76 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3AOC3HTR7 | |
| SCHEMBL14684800 | 0.76 | ALOX5 (0.42) | ALOX5PTGS2AOC3HTR7 | |
| SCHEMBL13964519 | 0.75 | PTGS2 (0.49) | ALOX5PTGS2AOC3CHRM2TAAR1 | |
| SCHEMBL5675723 | 0.75 | MEN1 (0.54) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276528-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7119122-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | CONNOLLY STEPHEN | 2006-09-28 | — | — | US | disclosed |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | disclosed |
| EP-1434756-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029185-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | disclosed |
| US-6251928-B1 | ADMINISTERING BENZYLIDENE RHODANINES WHICH ARE USEFUL AS AGENTS IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH BETA-AMYLOID PEPTIDE IN A MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-5747517-A | ALZHEIMER'S DISEASE; PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0677517-A1 | Treatment of Alzheimer's disease employing inhibitors of cathepsin D | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5393768-A | Treating hypersensitivity reactions such as asthma | ELI LILLY AND COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| US-5105017-A | Antiallergens | ELI LILLY AND COMPANY (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0132366-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1990-01-03 | — | — | EP | disclosed |
| EP-0132366-A2 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1985-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | NOS1, NOS3, NOS2 | SLC6A4 395/4885SLC6A2 870/4885SLC6A3 1351/4885 |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | NOS3, NOS1, NOS2 | SLC6A4 1110/4885SLC6A2 1537/4885SLC6A3 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.